StemCell Therapy

A Panamanian-led, multidisciplinary research team has published the first description of non-expanded fat stem cells in the treatment of rheumatoid arthritis patients. "Autologous Stromal Vascular Fraction Therapy for Rheumatoid Arthritis: Rationale and Clinical Safety," which appears in the January publication of the International Archives of Medicine, followed 13 rheumatoid arthritis patients who were treated with their own fat-derived stem cells.

Dallas, TX (PRWEB) February 21, 2012

A Panamanian-led, multidisciplinary research team has published the first description of non-expanded fat stem cells in the treatment of rheumatoid arthritis patients. "Autologous Stromal Vascular Fraction Therapy for Rheumatoid Arthritis: Rationale and Clinical Safety," which appears in the January publication of the International Archives of Medicine, followed 13 rheumatoid arthritis patients who were treated with their own fat-derived stem cells.

Treating arthritis with fat-derived stem cells has become commonplace in veterinary medicine over the past five years with over 7,000 horses and dogs treated by publication contributor Vet-Stem, a San Diego-based company. The objective of the joint Panamanian-US study was to determine feasibility of translating Vet-Stem's successful animal results into human patients.

Observing no treatment associated adverse reactions after one year, the team concluded that its protocol should be studied further to determine efficacy in the treatment of rheumatoid arthritis. Their publication details the rationale for the use of fat derived stem cells in treatment of autoimmune conditions and is freely available at: http://www.intarchmed.com/content/pdf/1755-7682-5-5.pdf

“Key to advancement of any medical protocol is transparent disclosure of rationale, treatment procedures and outcomes to the research community in a peer-reviewed and IRB-compliant manner,” said Dr. Jorge Paz Rodriguez, Medical Director of the Stem Cell Institute and research team leader. “While we have previously published case studies on the use of fat stem cells in multiple sclerosis patients, and one rheumatoid arthritis patient, this is the first time that comprehensive follow-up has been completed for a larger cohort of patients,” he added.

An important distinction that separates this particular approach from those which are being explored by several international investigators is that the fat stem cells were not grown in a laboratory, affording a substantially higher level of safety and protocol practicality.

“This work signifies Panama's emergence into the burgeoning field of translational medicine,” commented Dr. Ruben Berrocal Timmons, the Panamanian Secretary of Science and publication co-author. “We are proud to have attracted and collaborated with internationally-renowned stem cell clinical researchers such as Dr. Michael Murphy and Dr. Keith March from the Indiana University School of Medicine Center for Vascular Biology and Medicine, Dr. Boris Minev from the University of California, San Diego Moores Cancer Center, Dr. Chien Shing Chen from Loma Linda University Behavioral Medicine Center and Dr. Bob Harman from Vet-Stem. By leveraging their vast, collective clinical experience with Panamanian scientific infrastructure and know-how, we are striving to develop effective, internationally recognized stem cell procedures that will be accepted the world over.”

The treatment procedure involves a mini-liposuction, collection of the fat's cellular component, processing to obtain a population of cells that includes stem cells, freezing the cells in preparation for quality control, and subsequent re-administration of the cells into patients.

The Panamanian-US group has previously shown that there is a specific type of T cell, called the T regulatory cell, associated with fat stem cells, which is capable of suppressing pathological immunity. Their current theory, which is described in detail in the publication: http://www.ncbi.nlm.nih.gov/pubmed/20537320, is that the T regulatory component of the fat is capable of slowing down or suppressing the “autoimmune” reaction, while the stem cell component causes formation of new tissue to replace the damaged joints.

About the Stem Cell Institute

Founded in 2006 on the principles of providing unbiased, scientifically-sound treatment options, the Stem Cell Institute has matured into the world’s leading adult stem cell therapy and research center. In close collaboration with universities and physicians world-wide, the institute’s doctors treat carefully selected patients with spinal cord injury, osteoarthritis, heart disease, multiple sclerosis, rheumatoid arthritis and other autoimmune diseases. Doctors at The Stem Cell Institute have treated over 1000 patients to-date.

For more information on stem cell therapy:

Stem Cell Institute Web Site: http://www.cellmedicine.com

Facebook: http://www.facebook.com/stemcellinstitute

Blogger: http://www.adult-stem-cell-therapy.blogspot.com

Stem Cell Institute

Via Israel & Calle 66

Pacifica Plaza Office #2A

San Francisco, Panama

Republic of Panama

Phone: +1 800 980-STEM (7836) (USA Toll-free) +1 954 636-3390 (from outside USA)

Fax: +1 866 775-3951 (USA Toll-free) +1 775 887-1194 (from outside USA)

###

Jay Lenner
jdlenner@cellmedicine.com
1-800-980-7836
Email Information

Read the original:
Panamanian-US Scientific Research Supports Using Fat Stem Cells to Treat Rheumatoid Arthritis

Pet stem cells frozen and banked for future

ORLANDO, Fla. -

Eight Central Florida veterinary clinics are offering up a new procedure that could save or greatly improve a pet's life.

MediVet America has set up a holding center at the company's Nicholasville, Ken., lab to freeze and store pet stem cells for future use.  Clinical studies have shown the cells can be viable for decades.

The procedure extracts stem cells from the animal's own fat tissue. The cells are then treated and used for aging dogs and cats struggling with arthritis or degenerative disease for several years, with good results.

By "cryobanking," the healthy cells, they will be ready if needed in the future.

"Banking stem cells is like having an extra insurance policy for your pet," explained Jeremy Delk, CEO of MediVet America.

Dr. Daniel Evers of ValuVet is taking part in a pet stem cell project in Central Florida to determine if the stem cells are actually causing cartilage regeneration.

Twelve pets will be selected for the study, which will include two separate MRI scans to determine how effective the stem cell treatments are for pets struggling with joint issues.

[SHARE YOUR PHOTOS: Picture-perfect pets]

Normally, the initial cost is $420, with a $150 annual storage fee. Owners whose pets are selected will get a discount on the stem cell procedure. Pet owners interested in the procedure can contact Erica Kent at erica@medivet-america.com or call 386-748-4251.

Copyright 2012 by ClickOrlando.com. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Go here to see the original:
Pet stem cells frozen, banked for future

ScienceDaily (Feb. 19, 2012) — Researchers from King's College London have provided the first experimental evidence confirming a great British mathematician's theory of how biological patterns such as tiger stripes or leopard spots are formed.

The study, funded by the Medical Research Council and published online in Nature Genetics, not only demonstrates a mechanism which is likely to be widely relevant in vertebrate development, but also provides confidence that chemicals called morphogens, which control these patterns, can be used in regenerative medicine to differentiate stem cells into tissue.

The findings provide evidence to support a theory first suggested in the 1950s by famous code-breaker and mathematician Alan Turing, whose centenary falls this year. He put forward the idea that regular repeating patterns in biological systems are generated by a pair of morphogens that work together as an 'activator' and 'inhibitor'.

To test the theory the researchers studied the development of the regularly spaced ridges found in the roof of the mouth in mice. Carrying out experiments in mouse embryos, the team identified the pair of morphogens working together to influence where each ridge will be formed. These chemicals controlled each other's expression, activating and inhibiting production and therefore controlling the generation of the ridge pattern.

The researchers were able to identify the specific morphogens involved in this process -- FGF (Fibroblast Growth Factor) and Shh (Sonic Hedgehog -- so-called because laboratory fruit flies lacking the fly version have extra bristles on their bodies). They showed that when these morphogens' activity is increased or decreased, the pattern of the ridges in the mouth palate are affected in ways predicted by Turing's equations. For the first time the actual morphogens involved in this process have been identified and the team were able to see exactly the effects predicted by Turing's 60-year-old speculative theory.

Dr Jeremy Green from the Department of Craniofacial Development at King's Dental Institute said: 'Regularly spaced structures, from vertebrae and hair follicles to the stripes on a tiger or zebrafish, are a fundamental motif in biology. There are several theories about how patterns in nature are formed, but until now there was only circumstantial evidence for Turing's mechanism. Our study provides the first experimental identification of an activator-inhibitor system at work in the generation of stripes -- in this case, in the ridges of the mouth palate.

'Although important in feeling and tasting food, ridges in the mouth are not of great medical significance. However, they have proven extremely valuable here in validating an old theory of the activator-inhibitor model first put forward by Alan Turing in the 50s.

'Not only does this show us how patterns such as stripes are formed, but it provides confidence that these morphogens (chemicals) can be used in future regenerative medicine to regenerate structure and pattern when differentiating stem cells into other tissues.

'As this year marks Turing's centenary, it is a fitting tribute to this great mathematician and computer scientist that we should now be able to prove that his theory was right all along!'

Recommend this story on Facebook, Twitter,
and Google +1:

Other bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by King's College London.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

Andrew D Economou, Atsushi Ohazama, Thantrira Porntaveetus, Paul T Sharpe, Shigeru Kondo, M Albert Basson, Amel Gritli-Linde, Martyn T Cobourne, Jeremy B A Green. Periodic stripe formation by a Turing mechanism operating at growth zones in the mammalian palate. Nature Genetics, 2012; DOI: 10.1038/ng.1090

Note: If no author is given, the source is cited instead.

Disclaimer: Views expressed in this article do not necessarily reflect those of ScienceDaily or its staff.

Read this article:
Turing's tiger stripe theory demonstrated

(CBS News) 

How did the tiger get its stripes? Scientists in England say they've figured out the biological mechanisms behind the big cat's trademark look - and it's a bit more complicated than one of Kipling's Just So Stories.

According to researchers at King's College London, their findings, published in the journal Nature Genetics, confirm a theory put forth in the 1950s by mathematician and code-breaker Alan Turing, the man considered the father of the computer. 

Turing theorized that a pair of morphogens, substances that govern how cells develop into tissues, work together as an "activator" and "inhibitor" causing regular repeating patterns in biological systems. 

According to the Telegraph, "One of the chemicals, [Turing] suggested, triggered cell activity, while the other hindered it. The way in which they interact would dictate where cells grow, creating familiar patterns on the fur of animals."

To test this theory, the researchers tested a spot on another animal that shows such patterns - the evenly spaced ridges in the mouths of mice.

According to a post by King's College London:

Carrying out experiments in mouse embryos, the team identified the pair of morphogens working together to influence where each ridge will be formed. These chemicals controlled each other's expression, activating and inhibiting production and therefore controlling the generation of the ridge pattern...They showed that when these morphogens' activity is increased or decreased, the pattern of the ridges in the mouth palate are affected in ways predicted by Turing's equations.

Dr. Jeremy Green from the Department of Craniofacial Development at King's Dental Institute says that this is the "first experimental identification of an activator-inhibitor system at work in the generation of stripes" and better understanding of this process could, in future, be used "to regenerate structure and pattern when differentiating stem cells into other tissues."

Green also notes that, fittingly, this confirmation comes during Turing's centenary: he would have turned 100 this June.

See more here:
Alan Turing's tiger-stripe theory confirmed, say researchers

Dame Judi Dench, the actress who plays the steely-eyed boss keeping watch over James Bond, revealed she is losing her sight to macular degeneration.

"I can't read scripts anymore because of the trouble with my eyes," Dench, 77, told the Mirror. "And so somebody comes in and reads them to me, like telling me a story."

The macula is a small area in the center of the retina responsible for fine vision -- the kind needed to read or detect details in faces. With age, the macula can break down, and the blood vessels underneath can leak, causing blurriness and, eventually, a blind spot right in the center of the visual field.

"The most distressing thing is in a restaurant in the evening I can't see the person I'm having dinner with," Dench said.

Age-related macular degeneration is the leading cause of vision loss in people over 60, according to the National Eye Institute. In 2004, an estimated 1.75 million Americans had the disease -- a number likely to grow as the boomer population ages.

"It can be a visually devastating disease," said Dr. Martin Friedlander, chief or Retina Services at the Scripps Clinic in La Jolla, Calif. "Particularly because it affects people at a time in their lives when they are more dependent on their fine, or central, vision to do the things we all would like to enjoy in the golden years: read, play games, watch TV, enjoy art, and look at our grandchildren's faces."

Gareth Cattermole/Getty Images

Dench has a 15-year-old grandson, Sam.

The cause of age-related macular degeneration is unknown, but genes can contribute to it.

"People with a family history of macular degeneration have a higher risk," said Dr. Sophie Bakri, professor of ophthalmology at the Mayo Clinic in Rochester, Minn.

Dench revealed that her mother, too, lived with the disease.

Being white, female and blue-eyed, like Dench, may also increase the risk macular degeneration, according to the Mayo Clinic.

There are two types of macular degeneration: Dry, which is caused by a breakdown of the light-detecting cells of the macula; and wet, which is caused by the growth of abnormal, leaky blood vessels. Dench said she has the dry form in one eye and the wet form in the other.

"The presence of both forms in one person is not at all unusual," said Dr. Marco Zarbin, chairman of New Jersey Medical School's Institute of Ophthalmology and Visual Science in Newark.

Although neither form can be cured, both can be treated with the goal of slowing the degeneration and preventing vision loss.

"The most important innovation in the treatment of age-related macular degeneration ever was the introduction of drugs that block the action of vascular endothelial growth factor," said Zarbin, describing injectable drugs like Lucentis, which was approved by the U.S. Food and Drug Administration in 2005, that thwart the growth of abnormal blood vessels in wet macular degeneration. "That has allowed hundreds of thousands of people to preserve their vision and their independence."

In some cases, dry macular degeneration can be slowed with high doses of vitamins A, C and E as well as zinc and copper, Bakri said. And a tiny telescope can be surgically implanted into the eye to magnify the field of vision.

Experimental stem cell-based and gene therapy approaches have shown promise in treating macular degeneration, but Bakri said they're not yet ready for the clinic.

Dench told the Mirror she's getting injections and believes the disease has "arrested." Whatever happens, she has no plans to retire from acting.

"I'm very conscious that I'm in the minority in that I love what I do," she said. "And how lucky to be employed at it -- how incredibly lucky."

Original post:
Dame Judi Dench Battling Blindness

SAN CARLOS, Calif.--(BUSINESS WIRE)--

Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced that Lowell E. Sears joined its Board of Directors effective today.

Mr. Sears is currently Chairman and CEO of Sears Capital Management, a venture investment and portfolio management firm specializing in life sciences. He has been an active life science venture investor since 1994, helping to found and fund over forty companies. From 1986 until 1994, Mr. Sears was a part of the senior management team of Amgen, Inc., where he held positions of Chief Financial Officer as well as Senior Vice President responsible for the Asia Pacific Region.

"Lowell has had a distinguished biotechnology career and is highly regarded in the industry. I am delighted to welcome him to our board," said Ram Mandalam, President and CEO of Cellerant. "His broad experience in strategic planning, corporate financing and overall management and operational skills will be very useful to us as we continue to develop our programs and build shareholder value."

“On behalf of all of our directors I am delighted to welcome Lowell to our board," said Richard Rathmann, Cellerant’s Chairman of the Board. "Throughout his career at Amgen and other biotechnology companies, Lowell has been directly involved in building and developing successful companies as they advance to the next stage."

Prior to joining to Amgen, Mr. Sears held senior planning and financial positions with Atlantic Richfield Company (ARCO) from 1976 until 1986, including a period as Chief Financial Officer for its Ventures Division. Mr. Sears has served on twenty boards of directors, including roles as board chairman and audit committee chair. He currently serves on the board of SymBio Pharmaceuticals, KK, Ltd. (JASDAQ: 4582).

About Cellerant Therapeutics

Cellerant Therapeutics is a clinical stage biotechnology company focused on the regulation of the hematopoietic (blood-forming) system. The Company is developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant’s lead product, CLT-008, is currently in two Phase 1 clinical trials in patients with hematological malignancies. The Company also has a cancer stem cell (CSC) antibody discovery program focused on therapies for acute myelogenous leukemia, multiple myeloma and myelodysplastic syndrome.

For more information, visit: http://www.cellerant.com.

See more here:
Cellerant Therapeutics Appoints Lowell E. Sears to Board of Directors

15-02-2012 18:52 Jake is one of the first dogs in the area to receive same day stem cell therapy. The new treatment gives animals better treatment in a shorter timeframe. Jake suffers from arthritis and this procedure will help ease the pain.

Visit link:
Stem cell therapy makes dog happy again - Video

AUSTIN, Texas, Feb. 21, 2012 /PRNewswire/ -- Celling Biosciences announces a sponsorship of the 7th Annual Stem Cell Summit being held on February 21st at Bridgewaters New York in New York City. The Stem Cell Summit is consistently the premiere venue for the world's leaders in regenerative medicine to network and promote next generation technologies and cell therapies.

The meeting will feature more than 30 thought leaders in stem cell therapy including Dr. Kenneth Pettine of the Orthopedic Stem Cell Institute in Loveland, Colorado.  Dr. Pettine has teamed up with Celling Biosciences' SpineSmith Division to present "Adult Stem Cell Therapy for Orthopedic and Spine Conditions Resulting from Injury or Aging."  Dr. Pettine has become an innovator in the regenerative cell therapy market and believes "regenerative therapies will become the next standard of care in treating many orthopedic conditions." 

Following the Stem Cell Summit, Dr. Pettine will be presenting a discussion on regenerative therapies to the trainers and medical staff attending this year's NFL combine.  The NFL has recently gained attention from Peyton Manning going oversees to receive a cell therapy treatment for his cervical spine condition.  Dr. Pettine envisions a day when these professional athletes stop going to foreign countries to receive medical treatment.

The Orthopedic Stem Cell Institute provides state-of-the-art regenerative cell therapy using Celling Biosciences' ART 21 system. The ART 21 system processes bone marrow from the patient at the point of care to consistently produce a concentrate of regenerative cells with high yields of mononuclear stem cells in less than 15 minutes.  Celling Biosciences provides the cell separation systems along with the biomaterials and devices necessary to recreate the environment to promote healing. 

Kevin Dunworth, founder of Celling Biosciences, believes regenerative cell therapy has more to do with creating the optimal environment then just providing cells.  "We believe autologous cell therapy is a viable solution but physicians need to understand that these cells require the necessary substrate for delivery and the proper techniques for retrieval.  Our focus has been on providing not only cell separation technologies, medical devices and biomaterials but also the registered nurses to deliver the service so physicians can have the most consistent, reliable and predictable regenerative cell therapy for their patients."

Contact:
Tracy Gladden
Communications Manager
Tgladden@spinesmithusa.com
512-637-2050

About Celling Biosciences
Celling Biosciences, works closely with surgeons, scientists and engineers to research and develop innovative technologies in the field of regenerative medicine. http://www.cellingbiosciences.com and http://www.spinesmithusa.com

Continue reading here:
Celling Biosciences Sponsors 7th Annual Stem Cell Summit

AUSTIN, Texas, Feb. 21, 2012 /PRNewswire/ -- Celling Biosciences announces a sponsorship of the 7th Annual Stem Cell Summit being held on February 21st at Bridgewaters New York in New York City. The Stem Cell Summit is consistently the premiere venue for the world's leaders in regenerative medicine to network and promote next generation technologies and cell therapies.

The meeting will feature more than 30 thought leaders in stem cell therapy including Dr. Kenneth Pettine of the Orthopedic Stem Cell Institute in Loveland, Colorado.  Dr. Pettine has teamed up with Celling Biosciences' SpineSmith Division to present "Adult Stem Cell Therapy for Orthopedic and Spine Conditions Resulting from Injury or Aging."  Dr. Pettine has become an innovator in the regenerative cell therapy market and believes "regenerative therapies will become the next standard of care in treating many orthopedic conditions." 

Following the Stem Cell Summit, Dr. Pettine will be presenting a discussion on regenerative therapies to the trainers and medical staff attending this year's NFL combine.  The NFL has recently gained attention from Peyton Manning going oversees to receive a cell therapy treatment for his cervical spine condition.  Dr. Pettine envisions a day when these professional athletes stop going to foreign countries to receive medical treatment.

The Orthopedic Stem Cell Institute provides state-of-the-art regenerative cell therapy using Celling Biosciences' ART 21 system. The ART 21 system processes bone marrow from the patient at the point of care to consistently produce a concentrate of regenerative cells with high yields of mononuclear stem cells in less than 15 minutes.  Celling Biosciences provides the cell separation systems along with the biomaterials and devices necessary to recreate the environment to promote healing. 

Kevin Dunworth, founder of Celling Biosciences, believes regenerative cell therapy has more to do with creating the optimal environment then just providing cells.  "We believe autologous cell therapy is a viable solution but physicians need to understand that these cells require the necessary substrate for delivery and the proper techniques for retrieval.  Our focus has been on providing not only cell separation technologies, medical devices and biomaterials but also the registered nurses to deliver the service so physicians can have the most consistent, reliable and predictable regenerative cell therapy for their patients."

Contact:
Tracy Gladden
Communications Manager
Tgladden@spinesmithusa.com
512-637-2050

About Celling Biosciences
Celling Biosciences, works closely with surgeons, scientists and engineers to research and develop innovative technologies in the field of regenerative medicine. http://www.cellingbiosciences.com and http://www.spinesmithusa.com

Continue reading here:
Celling Biosciences Sponsors 7th Annual Stem Cell Summit

To: HEALTH AND NATIONAL EDITORS

VIRGINIA BEACH, Va., Feb. 20, 2012 /PRNewswire-USNewswire/ -- Rony Thomas, President and CEO of LifeNet Health, is presenting at the 7th Annual Stem Cell Summit in New York City on February 21, 2012. Mr. Thomas will be presenting on LifeNet Health's broad offerings of current and future regenerative biologic-based products. Mr. Thomas will also focus on the multiple new capabilities and technology platforms of the LifeNet Health Institute of Regenerative Medicine.

(Photo: http://photos.prnewswire.com/prnh/20120220/DC55479)

"The use of a variety of forms of donated tissues has worked for decades to save lives and restore health in many surgical disciplines. Now we are on the cusp of developing cellular therapies, tissue engineering and new medical applications for allografts to treat disease and assist in the development of lifesaving drugs. The opening of the LifeNet Health Institute of Regenerative Medicine this year will signal our commitment to future development in the cellular therapies arena," stated Mr. Thomas. Thomas will further focus on two new areas of development; Human Basement Membranes in zeno-free culture of consented Human mRNA Reprogrammed Induced Pluripotent Stem Cells and Induced Pluripotent Stem Cells (iPSc) derived using non-integrating mRNA reprogramming technology from fully consented queryable human donor banked system.

Mr. Thomas was also recently invited to and attended a White House Summit to discuss ways in which technology and innovation can drive employment opportunities for Virginia, where LifeNet Health and the Institute are located. The meeting of key CEOs with the Obama Administration was to gain insight and input on the job market and technology as a driver to local, state, and national economies. Thomas stated, "Our foray into regenerative medicine should not only impact our state and local economy, but provide medical benefits to patients and drug companies across the globe."

The annual Stem Cell Summit brings key leaders in the medical, scientific and business innovators in this growing space of technology and regenerative medicine. LifeNet Health is pleased to be joining the Summit for the first time in 2012 as they look for key partnerships and collaboration in the discovery of cell-based therapies for a broad spectrum of medical applications in orthopedics, trauma, dental, craniomaxillofacial (CMF), plastics, and cardiovascular surgery.

LifeNet Health helps to save lives and restore health for thousands of patients each year. We are the world's most trusted provider of transplant solutions, from organ procurement to new innovations in bio-implant technologies and cellular therapies--a leader in the field of regenerative medicine, while always honoring the donors and healthcare professionals that allow the healing process.

The LifeNet Health Institute of Regenerative Medicine is a division of LifeNet Health located in Virginia Beach, Virginia. The Institute's labs will be expanding as new facilities are under construction and planned to be completed in the fall of 2012. Once completed and fully functional, the Institute will house over 50 medical, scientific, and research staff members. The focus will be on the science of developing regenerative medicine products for patients all over the world, and will serve as a global center of excellence for research and development focused on cellular therapies, tissue engineering, and new medical applications for allografts to maximize the gift of donation.

SOURCE LifeNet Health

-0-

Read the original here:
LifeNet Health is Presenting at the 7th Annual Stem Cell Summit in New York on February 21, 2012

19-01-2012 22:48 Professor Trounson's presentation focuses on how stem cell research has the potential to yield groundbreaking new tools to understand and develop therapies for CP and related brain disorders. He also discusses the challenging nature of the research and its high risk to investigators which in many cases requires novel interdisciplinary collaborations and an increased focus on translations. Professor Alan Trounson is President of the California Institute for Regenerative Medicine (CIRM) in California, the state's $3 billion stem cell agency. He is a pioneer of human IVF and associated reproductive technologies including diagnosis of inherited genetic disease in pre-implantation embryos, and the discovery and production of human embryonic stem cells and their directed differentiation into a range of cell and tissue types.

Continue reading here:
Professor Alan Trounson - World focus on stem cell research - Video

08-02-2012 18:24 (October 25, 2011) Associate Professor at the Stanford School of Medicine, Joseph Wu explores how stem cells may be used in the future to repair hearts that have failed. This course is a single-quarter, focused follow-up to the the yearlong Mini Med School that occurred in 2009-10. The course focuses on diseases of the heart and cardiovascular system. The course is sponsored by Stanford Continuing Studies and the Stanford Medical School. Stanford University http://www.stanford.edu Stanford Continuing Studies http:///continuingstudies.stanford.edu/ Stanford University School of Medicine med.stanford.edu Stanford University Channel on YouTube: http://www.youtube.com

Read more here:
5. Stem Cells for Cardiac Repair | Mini Med School - Video

14-02-2012 11:04 CNN's Dr. Sanjay Gupta reports on a new stem cell therapy that might heal damage after a heart attack.

Read more here:
Heart stem cells repair muscle damage - Video

08-02-2012 23:17 NicholasAnderson.info Nicholas Anderson, Author of "NOC British Secret Operations" interviewed by Joseph Dowdy. stem cell transplantation... can't say diseases to get hopes up. oversaw exfiltration of doctor who is an expert at stem cell transplantation. not an expert or doctor, but can speak from experience. much of this may bother others. there is an assumption one belief is correct and others are wrong. stem cells are human and animal organisms derived from embryos. they can renew themselves in others bodys/cells/tissues. they are not factory assembled. they are coming from aborted tissue that would be thrown away. in the soviet union, they experimented on them. again, author does not know all about stem cells. speak to your doctor and do your own research. for most basic info on the doctor from the soviet union, see the book. was this post cold war debriefing? was he a scientist who knew a lot? no. he defected in mid-70s. the west/us/uk milked him for info. they did nothing with that info. he returned to the new russia after the collapse and started again. what has he been doing since? is the russian medicine better?? yes, it's more advanced or the west has simply got their advancements from russia. this is like a replacement battery for tissue/cells/body; it must be recharged. it does offer terminally ill chance to live longer; not a medical diagnosis. if people know enough about stem cells, they probably know what it is... it's good for regenerating tissue without ...

Follow this link:
Insights Into MI6: Stem Cell Transplantation - Video

13-02-2012 21:11 Documenting THE CURE is a funding project to write a book about patients leaving the US to receive natural healing Stem Cell treatments in Panama. DONATE: http://www.kickstarter.com The FDA ban on all stem cell treatments forces Americans to seek adult (non-embryonic) stem cell treatments offshore. This new type of stem cell treatment is documented in Dr. Roger Nocera's new book, Cells That Heal Us From Cradle To Grave: A Quantum Leap in Medical Science. JL Thompson will document the effectiveness of this treatment on an MS patient, and other patients seeking treatment at the Panama clinic.

The rest is here:
Documenting THE CURE: Seeking Stem Cell Healing Offshore -- MS patient - Video

29-01-2012 13:44 Stem Cell to Cure Kidney Problem. More Details Visit : http://www.kidneycurecenter.com

Here is the original post:
Kidney Cure Center - Video

15-02-2012 13:33 Hear from one of NSCF's post-transplant patients, the father of four. Rob requires no anti-rejection medication more than two years after a combination kidney/stem cell transplant in a clinical trial NSCF funds. NSCF currently supports research and clinical trial collaborations between Duke University, Northwestern University and University of Louisville. NSCF funds clinical trials to: • Induce drug-free tolerance for transplanted kidneys • Effectively cure inherited red blood cell disorders like sickle cell disease (SCD) and thalassemia •Permanently correct fatal childhood enzyme deficiencies For more information visit nationalstemcellfoundation.org.

Original post:
Rob Waddell's Story - Combination Kidney/Adult Stem Cell Transplant - Video

12-11-2011 21:49 Mr. Stolyarov provides a layman-friendly discussion of two recent major scientific discoveries in the war on senescence by Darren Baker and Jan van Deursen at the Mayo Clinic in Minnesota and Jean-Marc Lemaitre at the Institute de Génomique Fonctionnelle (IGF) in France. The Baker/van Deursen study highlights the possibility of extending health by targeting senescent cells. The Lemaitre study shows the promising possibility of creating pluripotent stem cells from the cells of very old individuals - paving the way for future genetic engineering and revitalization of these individuals. Both advances are highly encouraging steps in understanding and reversing the ravages of aging and eventually greatly expanding the human lifespan. References: * "Purging Cells in Mice Is Found to Combat Aging Ills" by Nicholas Wade, The New York Times. November 3, 2011. http://www.nytimes.com * "Forever young? A way to counteract part of the process of growing old". The Economist. November 5, 2011. http://www.economist.com * "Scientists Successful in Rejuvenating Cells in Elderly Patients" by Tiffany Kaiser. Daily Tech. November 8, 2011. http://www.dailytech.com * "French Scientists Restored The Youth Of 100 Years Old Cells" by Andrei Riciuon. DoctorTipster.com. November 2, 2011. http://www.doctortipster.com

Continued here:
Combating Aging's Ravages - Advances in Minnesota and France - Video

26-01-2012 07:54 Air date: Wednesday, January 25, 2012, 3:00:00 PM Timedisplayed is Eastern Time, Washington DC Local Category: Wednesday Afternoon Lectures Description: Patients with diseased or injured organs may be treated with transplanted organs. There is a severe shortage of donor organs which is worsening yearly due to the aging population. Regenerative medicine and tissue engineering apply the principles of cell transplantation, material sciences, and bioengineering to construct biological substitutes that may restore and maintain normal function in diseased and injured tissues. Stem cells may offer a potentially limitless source of cells for tissue engineering applications and are opening new options for therapy. Recent advances that have occurred in regenerative medicine will be reviewed and applications of these new technologies that may offer novel therapies for patients with end-stage tissue and organ failure will be described. The NIH Wednesday Afternoon Lecture Series includes weekly scientific talks by some of the top researchers in the biomedical sciences worldwide. For more information, visit: The NIH Director's Wednesday Afternoon Lecture Series Author: Anthony Atala, MD, Wake Forest School of Medicine Runtime: 00:51:29 Permanent link: videocast.nih.gov

Read more:
Regenerative Medicine: Current Concepts and Changing Trends - Video

05-01-2012 13:13 BioLife Cell Bank co-founder and medical director, Dr. David G. Genecov discusses how BioLife fat and stem cell banking originated. BioLife Cell Bank in Dallas is the first in the world to preserve fat and stem cells for future use in cosmetic and regenerative medical treatments. Fat (and the stem cells within it) are extracted through liposuction and sent to BioLife Cell Bank in a special kit. BioLife processes and cryopreserves the cells so that they are available for future use in a variety of reconstructive, aesthetic and therapeutic treatments. http://www.biolifecellbank.com

View post:
Dr. Genecov Shares How BioLife Cell Bank Was Born - Video